Androgel > Texas
Please select a testosterone article from the list below:
- Business Wire - Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
- Business Wire - Repros' Androxal Shows Noninferiority in Interim Phase 3 Analysis
- Business Wire - Zonagen Presents Data for Androxal in the Treatment of Hypogonadal Men and Data for Progenta as a Potential New Approach in the Treatment of Breast Cancer
- Business Wire - Zonagen Reports Initial Findings Comparing Androxal to Androgel From U.S. Phase I/II Safety and Efficacy Study in Men with Low Testosterone
- Business Wire - Zonagen's Androxal Achieves Statistically Significant Results versus Placebo in U.S. Phase I/II Safety and Efficacy Study in Men with Low Testosterone
Tuesday 5th of June 2007
Business Wire - Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
Tuesday 5th of June 2007, 12:00 amJune 5, 2007 -- Non-Inferiority to Market Leading Drug Demonstrated in Six Month Study THE WOODLANDS, Texas -- Repros Therapeutics Inc. (NasdaqGM:RPRX) announced...
Wednesday 20th of December 2006
Business Wire - Repros' Androxal Shows Noninferiority in Interim Phase 3 Analysis
Wednesday 20th of December 2006, 12:00 amDecember 20, 2006 -- THE WOODLANDS, Texas -- Repros Therapeutics Inc. (NasdaqGM:RPRX)(PCX:RPRX) announced interim results of a U.S. Phase 3 study of Androxal[TM], an oral...
Thursday 2nd of September 2004
Business Wire - Zonagen Presents Data for Androxal in the Treatment of Hypogonadal Men and Data for Progenta as a Potential New Approach in the Treatment of Breast Cancer
Thursday 2nd of September 2004, 12:00 amSeptember 2, 2004 -- THE WOODLANDS, Texas -- Data to Be Presented at the 12th International Congress of Endocrinolgy in Lisbon Portugal Zonagen, Inc....
Thursday 15th of July 2004
Business Wire - Zonagen Reports Initial Findings Comparing Androxal to Androgel From U.S. Phase I/II Safety and Efficacy Study in Men with Low Testosterone
Thursday 15th of July 2004, 12:00 amJuly 15, 2004 -- THE WOODLANDS, Texas -- Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZNG) today released additional results from a randomized clinical trial comparing...
Thursday 1st of July 2004
Business Wire - Zonagen's Androxal Achieves Statistically Significant Results versus Placebo in U.S. Phase I/II Safety and Efficacy Study in Men with Low Testosterone
Thursday 1st of July 2004, 12:00 amJuly 1, 2004 -- THE WOODLANDS, Texas -- Zonagen Updates Status of Androxal(TM) Intellectual Property Zonagen, Inc. (Nasdaq:ZONA)(PCX:ZNG) today released results...